Ezogabine, an FDA approved anti-convulsant, appears to significantly reduce symptoms in those with major depressive disorder.
Researchers discover changes in the activity of sodium and potassium channels during the day and night impact the sleep-wake cycle.
A study suggests that spinal muscular atrophy (SMA), a genetic neuromuscular disease in infants and children, results primarily from motor circuit dysfunction, not motor neuron or muscle cell dysfunction, as is commonly thought. In a second study, the researchers identified the molecular pathway in SMA that leads to problems with motor function.
Ezogabine, a drug that opens up the KCNQ2/3 type potassium channel, significantly improved symptoms of depression and anhedonia.
A new study reports researchers have used whole genome sequencing to identify a new genetic cause of epileptic encephalopathy.
GABA can selectively regulate the excitability of neurons.